{"organizations": [], "uuid": "0f66b95d5f704bd1c075b7cb85981b7dfd679590", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/zentiva-leveraged-loans/bank-trio-expected-to-lead-financing-on-zentiva-sale-idUSL8N1RU35P", "country": "US", "domain_rank": 408, "title": "Bank trio expected to lead financing on Zentiva sale", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-04-17T18:54:00.000+03:00", "replies_count": 0, "uuid": "0f66b95d5f704bd1c075b7cb85981b7dfd679590"}, "author": "Claire Ruckin", "url": "https://www.reuters.com/article/zentiva-leveraged-loans/bank-trio-expected-to-lead-financing-on-zentiva-sale-idUSL8N1RU35P", "ord_in_thread": 0, "title": "Bank trio expected to lead financing on Zentiva sale", "locations": [], "entities": {"persons": [{"name": "zentiva", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "zentiva", "sentiment": "none"}], "organizations": [{"name": "bank", "sentiment": "negative"}, {"name": "goldman sachs", "sentiment": "negative"}, {"name": "jp morgan", "sentiment": "negative"}, {"name": "morgan stanley", "sentiment": "negative"}, {"name": "advent international", "sentiment": "none"}, {"name": "zentiva", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, April 17 (LPC) - Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s European generics drugs arm Zentiva, banking sources said.\nSanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.\nThe three banks are expected to lead the financing but have yet to receive a formal mandate.\nUp to six additional banks are expected to be mandated shortly on the financing as banks backing Advent and the other bidders during an auction process for the unit pitch to Advent to win a spot on the deal.\nThe financing closely mirrors a staple financing offered during the sale process, which totalled around 7.0 times Zentiva’s approximate €155m Ebitda.\nIt is expected to include around €1bn-€1.1bn of drawn debt, including senior leveraged loans and subordinated second-lien loans as well as additional undrawn facilities.\nAdvent declined to comment.\nThe planned sale of Zentiva began in October after Sanofi spent more than a year carving out the division to create a stand-alone company that could be sold to one of its competitors or to an investment fund.\nIn February, sources told Reuters that private equity firms Carlyle, BC Partners and a consortium of Blackstone and Nordic Capital had been shortlisted to buy Zentiva along with two industry players, Brazilian drugs firm EMS and India’s Torrent Pharma.\nZentiva operates in 50 markets and has a strong presence in Eastern Europe, particularly in the Czech Republic, Slovakia and Romania.\nEditing by Christopher Mangham\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T18:54:00.000+03:00", "crawled": "2018-04-18T18:36:10.002+03:00", "highlightTitle": ""}